Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 11Neoplasm Metastasis 5Carcinoma 4Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2NSCLC 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stage II-IIIB Non-small Cell Lung Carcinoma 1Stage IB-IIIA Non-small Cell Lung Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Carcinoma 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Melanoma 1Head and Neck Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

pelcitoclax 1osimertinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × EGFR Positive Non-small Cell Lung Cancer × osimertinib × Clear all
NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡